Registry models estimate lead-extraction adverse-event labels
Source check: Source checked. Not independent scientific confirmation.
Finding: Models trained on European lead-extraction registry data were evaluated against major adverse events in a separate UK series. A support-vector classifier reported an ROC area of0.764 versus0.677 for the EROS score. Test-set feature selection limits this as a fully independent assessment, and neural scores were not calibrated individual probabilities.
Technology: Support vector machine; shallow neural network
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Fitted classifiers map registry clinical/procedural features to documented major adverse-event labels.
- Test and result
- The analyzed development group contained3122 patients with53 events and the analyzed UK group998 with24 events; nominal recruited cohort sizes were3555 and1171. Registry-overlapping UK patients were removed.
- Limitation / still unknown
- Sequential backward feature selection explicitly used the test dataset, so the external series was not untouched. Missing binary records were excluded and other values imputed as normal. The source percent for3122/3555 is inconsistent. Neural softmax scores should not be interpreted as calibrated individual event probabilities; no prospective decision benefit or statistically established superiority is claimed. The original publisher publication history gives online publication on April 27, 2022, while PubMed records April 28; the represented date follows the original publisher.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.diva-portal.org/smash/get/diva2%3A1739000/FULLTEXT01.pdf · https://doi.org/10.1016/j.hrthm.2021.12.036
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 21 Nov 2026. Review scope: Actual relevant primary computational/clinical Methods and high-level Results read; no operational biological protocols inspected; original indexed publisher publication history and PubMed date conflict checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.